Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison
Balázs Halmos, Thomas Burke, Chrysostomos Kalyvas, Kristel Vandormael, Andrew M. Frederickson, Bilal Piperdi
Topics & Concepts
AtezolizumabMedicinePembrolizumabBevacizumabChemotherapyOncologyInternal medicineCancerImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations